Leaflet LUMOBRY 0.25mg / ml ophthalmic drops solution


Indicated for: glaucoma; ocular hypertension

Substance: brimonidine (glaucoma agent)

ATC: S01GA07 (Sensory organs | Decongestants and antiallergics | Sympathomimetics used as decongestants)

Brimonidine is a medication used to treat open-angle glaucoma and ocular hypertension. It belongs to the class of alpha-2 adrenergic receptor agonists and works by reducing the production of aqueous humor and increasing its outflow, thereby lowering intraocular pressure.

It is available as eye drops and is typically administered two to three times a day, as directed by a doctor. Brimonidine is effective in preventing optic nerve damage caused by elevated intraocular pressure.

Side effects may include a burning or stinging sensation in the eyes, dry eyes, redness, headache, drowsiness, or dizziness. It is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs) and should be used with caution in those with severe cardiovascular conditions.

General data about LUMOBRY 0.25mg / ml

  • Substance: brimonidine
  • Date of last drug list: 01-07-2024
  • Commercial code: W70321001
  • Concentration: 0.25mg / ml
  • Pharmaceutical form: ophthalmic drops solution
  • Quantity: 1
  • Product type: original
  • Prescription restrictions: P-6L - Medicines prescription that isn't retained in the pharmacy (can be renewed); the prescription can be used for 6 months from the moment of release.

Marketing authorisation

  • Manufacturer: BAUSCH+LOMB IRELAND LIMITED - IRLANDA
  • Holder: BAUSCH+LOMB IRELAND LIMIT - IRLANDA
  • Number: 15476/2024/01
  • Shelf life: 2 years-after packaging for sale;after the first opening of the bottle-121 days

Pharmaceutical forms available for brimonidine

Concentrations available for brimonidine

  • 0.25mg/ml
  • 2mg/ml
  • 3mg/g

Combinations with other substances